NO20052222L - Farmasoytisk preparat omfattende krystallinsk sibutraminmetansulfonathemihydrat - Google Patents

Farmasoytisk preparat omfattende krystallinsk sibutraminmetansulfonathemihydrat

Info

Publication number
NO20052222L
NO20052222L NO20052222A NO20052222A NO20052222L NO 20052222 L NO20052222 L NO 20052222L NO 20052222 A NO20052222 A NO 20052222A NO 20052222 A NO20052222 A NO 20052222A NO 20052222 L NO20052222 L NO 20052222L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
methanesulfonate hemihydrate
crystalline
sibutramine
crystalline sibutramine
Prior art date
Application number
NO20052222A
Other languages
English (en)
Inventor
Gha-Seung Park
Jae-Heon Lee
Jae-Cheol Lee
Han-Kyong Kuri
Young-Kil Chang
Gwan-Sun Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2003-0053752A external-priority patent/KR100536750B1/ko
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of NO20052222L publication Critical patent/NO20052222L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Metallurgy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Farmasøytisk preparat for behandling eller forhindring av fedme, omfattende et krystallinsk sibuttamin-metansulfonathemihydrat med formel (I).Det krystallinske sibutiamin- metansulfonathemihydrat har en mye høyere løsehghet i vann, og forsterket stabilitet ved beting- elser med høy fiiktighet/tempera- tur, sammenhgnet medsibuttamin-hydrogenkloridmonohydrat. Farmasøytisk preparat for behand- ling eller forhindring av fedtne, omfattende et krystallinsk sibutramin-metansulfonathemihydrat med formel (1). jdV Det krystallinske sibutramin- metansulfonathemihydrat har en mye høyere løselighet i vann, og forsterket stabilitet ved beting- elser med høy fuktighet/tempera- tur, sammenlignet med sibutramin- hydrogenkloridmonohydrat.
NO20052222A 2002-10-05 2005-05-06 Farmasoytisk preparat omfattende krystallinsk sibutraminmetansulfonathemihydrat NO20052222L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20020060798 2002-10-05
KR10-2003-0053752A KR100536750B1 (ko) 2002-10-05 2003-08-04 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
PCT/KR2003/001955 WO2004030663A1 (en) 2002-10-05 2003-09-25 Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate

Publications (1)

Publication Number Publication Date
NO20052222L true NO20052222L (no) 2005-05-06

Family

ID=36147018

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052222A NO20052222L (no) 2002-10-05 2005-05-06 Farmasoytisk preparat omfattende krystallinsk sibutraminmetansulfonathemihydrat

Country Status (14)

Country Link
US (1) US6900245B2 (no)
EP (1) EP1545484A4 (no)
JP (1) JP4278652B2 (no)
AU (1) AU2003264968B2 (no)
BR (1) BR0315084A (no)
CA (1) CA2501321C (no)
HK (1) HK1083741A1 (no)
HR (1) HRP20050307A2 (no)
MX (1) MXPA05003355A (no)
NO (1) NO20052222L (no)
NZ (1) NZ538966A (no)
PL (1) PL375032A1 (no)
RU (1) RU2290924C2 (no)
WO (1) WO2004030663A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
US20060084636A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
KR20060080817A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
EP1846359A4 (en) * 2005-01-06 2010-03-31 Cj Cheiljedang Corp INORGANIC ACID SALTS OF SIBUTRAMINE
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
JP4934293B2 (ja) * 2005-07-05 2012-05-16 コスモ石油株式会社 植物活力剤組成物
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
KR100806673B1 (ko) 2006-06-23 2008-03-03 주식회사 대희화학 결정상 시부트라민 프리베이스의 제조방법
KR20100088992A (ko) * 2009-02-02 2010-08-11 주식회사 대희화학 (ｒ)-시부트라민 염 및 그의 제조방법
US8629178B2 (en) * 2009-11-03 2014-01-14 Li Liu Sodium tanshinone IIA sulfonate hydrate and preparation method and use thereof
CN102786444A (zh) * 2012-07-24 2012-11-21 上海瑞博化学有限公司 一种***类似物的磺酸盐的制备方法
US11197896B2 (en) * 2014-08-25 2021-12-14 Société des Produits Nestlé S.A. Egg protein formulations and methods of manufacture thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB2098302B (en) * 1981-05-13 1985-02-06 Fort Vale Eng Ltd Improvements in lids for pressure vessels
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
WO2000056310A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
AU3894600A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6376552B1 (en) * 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Treatment of gallstones
US6355685B1 (en) * 1999-03-19 2002-03-12 Knoll Pharmaceutical Company Method of treating anxiety disorders
SI1169029T1 (sl) * 1999-03-19 2005-12-31 Abbott Gmbh & Co Kg Uporaba sibutramina ali njegova derivata za zdravljenje motenj med spanjem
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6232347B1 (en) * 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
WO2002036540A2 (en) * 2000-11-02 2002-05-10 Torrent Pharmaceuticals Ltd PROCESS FOR PREPARATION OF β-PHENETHYLAMINE DERIVATIVE

Also Published As

Publication number Publication date
CA2501321C (en) 2008-07-08
AU2003264968B2 (en) 2006-03-16
JP4278652B2 (ja) 2009-06-17
AU2003264968A1 (en) 2004-04-23
MXPA05003355A (es) 2005-10-18
US20040068018A1 (en) 2004-04-08
RU2005109560A (ru) 2005-09-20
PL375032A1 (en) 2005-11-14
NZ538966A (en) 2006-11-30
HK1083741A1 (en) 2006-07-14
CA2501321A1 (en) 2004-04-15
HRP20050307A2 (en) 2006-12-31
RU2290924C2 (ru) 2007-01-10
EP1545484A4 (en) 2010-01-13
US6900245B2 (en) 2005-05-31
EP1545484A1 (en) 2005-06-29
JP2006506449A (ja) 2006-02-23
BR0315084A (pt) 2005-08-16
WO2004030663A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
NO20052222L (no) Farmasoytisk preparat omfattende krystallinsk sibutraminmetansulfonathemihydrat
NO20012158L (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
GB0223038D0 (en) Therapeutic compounds
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
WO2006125101A3 (en) Raf inhibitor compounds and methods of use thereof
NO20075099L (no) Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer
RS65704A (en) Aza-arylpiperazines
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
WO2007027855A3 (en) Raf inhibitor compounds and methods of use thereof
IS7979A (is) 1,2,3-þríútskiptar arýl- og heteróarýlafleiður sem efnaskiptastillar og fyrirbygging og meðhöndlun tengdra sjúkdóma eins og sykursýki og blóðsykurshækkun
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
EA200300205A1 (ru) Производные пиразола и их применение в качестве ингибиторов протеинкиназы
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
WO2005019190A3 (en) (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
IS7840A (is) 3-(3,5-díoxó-4,5-díhýdró-3H-(1,2,4)tríasín-2-ýl)-bensamíð afleiður sem P2X7-hindrar til notkunar í meðferð á bólguvaldandi sjúkdómum
TW200604179A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
WO2006087077A3 (de) Hsp90 hemmende triazolderivate
NO20045215L (no) Anvendelse av tio-oxindolderivater for behandling av hudlidelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application